VBI Vaccines (VBIV) on Wednesday said that dosing has commenced in the second phase 2a/2b study evaluating VBI-2601 candidate as an add-on therapy to the...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
VBI Vaccines (VBIV) said Thursday it has filed a new-drug submission to Health Canada for the company's 3-antigen prophylactic hepatitis B vaccine...
VBI Vaccines (VBIV) said Wednesday that the Food and Drug Administration has approved PreHevbrio for the prevention of infection caused by hepatitis B...
| Address | 222 3rd Street Cambridge, Massachusetts 02142 |
| Phone | +1.617.830.3031 |
| Number of Employees | 112 |
| President, Chief Executive Officer & Director | Jeff Baxter |
| CFO, Director & Head-Business Development | Christopher McNulty |
| Chief Medical Officer | Francisco Diaz-Mitoma |
| Chief Scientific Officer | David Evander Anderson |
| Price Open | $1.80 |
| Previous Close | $1.83 |
| 52 Week Range | $1.74 - 4.83 |
| Market Capitalization | $447.7 M |
| Shares Outstanding | 257.3 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/01/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.26 |
| Beta vs. S&P 500 | N/A |
| Revenue | $3.4 M |
| Net Profit Margin | -9,290.20% |
| Return on Equity | -39.02% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
